Extract
In chronic obstructive pulmonary disease (COPD), exacerbation history is the strongest predictor of future exacerbation risk [1, 2]. Large cohort studies have shown that patients with one exacerbation in the previous year have an approximately two-fold increased future exacerbation risk compared to patients with no exacerbations, the risk increasing to five-fold in those with two or more exacerbations [1, 2]. Most clinical trials of pharmacological treatments designed to prevent exacerbations have therefore used the inclusion criterion of at least one exacerbation in the previous year, with a minority requiring at least two exacerbations [3–6].
Abstract
In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXC
Acknowledgements
The three studies described in this manuscript were funded by Chiesi Farmaceutici SpA, as were the analyses presented here. Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This support was funded by Chiesi Farmaceutici SpA.
Footnotes
The TRILOGY, TRINITY and TRIBUTE studies are registered at ClinicalTrials.gov as NCT01917331, NCT01911364 and NCT02579850, respectively
Conflict of interest: D. Singh reports personal fees from Chiesi, during the conduct of these studies; grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, personal fees from Genentech and Skeypharma, outside the submitted work.
Conflict of interest: L.M. Fabbri reports personal fees and non-financial support from AstraZeneca, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon and Pearl Therapeutics, grants, personal fees and non-financial support from Chiesi, non-financial support from Dompe, outside the submitted work.
Conflict of interest: M. Corradi reports grants and personal fees from Chiesi Farmaceutici SpA, outside the submitted work.
Conflict of interest: G. Georges was an employee of Chiesi USA, Inc., during the conduct of these studies.
Conflict of interest: A. Guasconi was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies.
Conflict of interest: S. Vezzoli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies.
Conflict of interest: S. Petruzzelli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies.
Conflict of interest: A. Papi reports fees for board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, fees for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon, grants for research from Sanofi, outside the submitted work.
Support statement: The analyses presented here were funded by Chiesi Farmaceutici SpA. D. Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 24, 2019.
- Accepted February 12, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.